Biologically active substance-secreting hybrid gel
AssigneesResearch Development Corporation of Japan, Genentech, Inc.
InventorsSusumu Yoshida, R. Andrew Cuthbertson, Katsutoshi Yoshizato
Life of this patent
Estimating the term…
Abstract
The present invention provides a biologically active substance secreting hybrid gel, which consists essentially of a biopolymeric gel and cells containing an expression vector with a gene encoding the biologically active substance to produce the substance. According to the present invention, it is possible to develop a gene therapy by skin transplantation allowing stable drug medication for a long time; alleviating pains of patients; and allowing fine adjustment of the dosage and control of genes externally without using retrovirusderived vector that tend to invoke the risk of mutation to wild types as in the conventional prescription.
Claims7
An artificial skin secreting human proinsulin, human insulin, or both human proinsulin and insulin, which consists essentially of (1) a mixture of biopolymer gel and skin fibroblasts and (2) skin epidermal cells overlaid on the mixture of biopolymer gel and skin fibroblasts, wherein said epidermal cells or both said skin fibroblasts and said epidermal cells are transformed with a recombinant expression vector comprising a DNA sequence expressing human proinsulin or human insulin, or both human proinsulin and insulin.
Dependencies are inferred from the claim text.